Menarini Asia-Pacific announces an exclusive partnership with Pharmacosmos A/S to register, commercialise, and distribute Cosela (trilaciclib) across the company’s Asia-Pacific markets. The agreement focuses on bringing the therapy to patients in the region, with Cosela described as an oncology supportive care treatment. Across the reports, the therapy’s target is chemotherapy-induced myelosuppression (CIM), a side effect that can damage bone marrow and affect its ability to produce healthy blood cells. The outlets cite that CIM is a potentially debilitating consequence of chemotherapy and that Cosela is positioned to help address this supportive-care need. The announcement appears to originate from a press release disseminated by PRNewswire, and the coverage is consistent in naming the two companies, the scope of activities (registration, commercialisation, and distribution), and the regional intent (Asia-Pacific). No additional details are provided in the excerpts regarding timelines, specific countries included, or regulatory status, beyond the stated aim to register and commercialise the product in the region.